Page 49 - Read Online

Lo. Hepatoma Res 2019;5:41 I http://dx.doi.org/10.20517/2394-5079.2019.021 Page 7 of 7

40. Sugiki T, Yamamoto M, Taka K, Nakano M. Specific characteristics of scirrhous hepatocellular carcinoma. Hepatogastroenterology
2009;56:1086-9.
41. Kim SH, Lim HK, Lee WJ, Choi D, Park CK. Scirrhous hepatocellular carcinoma: comparison with usual hepatocellular carcinoma
based on CT-pathologic features and long-term results after curative resection. Eur J Radiol 2009;69:123-30.
42. Edmondson HA. Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood. AMA J Dis Child
1956;91:168-86.
43. Craig JR, Peters RL, Edmondson HA, Omata M. Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with
distinctive clinico-pathologic features. Cancer 1980;46:372-9.
44. Eggert T, McGlynn KA, Duffy A, Manns MP, Greten TF, et al. Fibrolamellar hepatocellular carcinoma in the USA, 2000-2010:
a detailed report on frequency, treatment and outcome based on the surveillance, epidemiology, and end results database. United
European Gastroenterol J 2013;1:351-7.
45. Torbenson M. Fibrolamellar carcinoma: 2012 update. Scientifica (Cairo) 2012;2012:743790.
46. Choi WT, Ramachandran R, Kakar S. Immunohistochemical approach for the diagnosis of a liver mass on small biopsy specimens.
Hum Pathol 2017;63:1-13.
47. Mayo SC, Mavros MN, Nathan H, Cosgrove D, Herman JM, et al. Treatment and prognosis of patients with fibrolamellar
hepatocellular carcinoma: a national perspective. J Am Coll Surg 2014;218:196-205.
48. Honeyman JN, Simon EP, Robine N, Chiaroni-Clarke R, Darcy DG, et al. Detection of a recurrent DNAJB1-PRKACA chimeric
transcript in fibrolamellar hepatocellular carcinoma. Science 2014;343:1010-4.
49. Engelholm LH, Riaz A, Serra D, Dagnaes-Hansen F, Johansen JV, et al. CRISPR/Cas9 engineering of adult mouse liver demonstrates
that the dnajb1-prkaca gene fusion is sufficient to induce tumors resembling fibrolamellar hepatocellular carcinoma. Gastroenterology
2017;153:1662-73.e10.
50. Kastenhuber ER, Lalazar G, Houlihan SL, Tschaharganeh DF, Baslan T, et al. DNAJB1-PRKACA fusion kinase interacts with beta-
catenin and the liver regenerative response to drive fibrolamellar hepatocellular carcinoma. Proc Natl Acad Sci U S A 2017;114:13076-84.
51. Turnham RE, Smith FD, Kenerson HL, Omar MH, Golkowski M, et al. An acquired scaffolding function of the DNAJ-PKAc fusion
contributes to oncogenic signaling in fibrolamellar carcinoma. Elife 2019;8:e44187.
52. Brunt E, Aishima S, Clavien PA, Fowler K, Goodman Z, et al. cHCC-CCA: consensus terminology for primary liver carcinomas with
both hepatocytic and cholangiocytic differentation. Hepatology 2018;68:113-26.
53. Gigante E, Ronot M, Bertin C, Ciolina M, Bouattour M, et al. Combining imaging and tumor biopsy improves the diagnosis of
combined hepatocellular-cholangiocarcinoma. Liver Int 2019.
54. Mihara Y, Akiba J, Ogasawara S, Kondo R, Fukushima H, et al. Malic enzyme 1 is a potential marker of combined hepatocellular
cholangiocarcinoma, subtype with stem-cell features, intermediate-cell type. Hepatol Res 2019;49:1066-75.
55. Garancini M, Goffredo P, Pagni F, Romano F, Roman S, et al. Combined hepatocellular-cholangiocarcinoma: a population-level
analysis of an uncommon primary liver tumor. Liver Transpl 2014;20:952-9.
56. He C, Zhang Y, Cai Z, Lin X. Competing risk analyses of overall survival and cancer-specific survival in patients with combined
hepatocellular cholangiocarcinoma after surgery. BMC Cancer 2019;19:178.
57. De Vito C, Sarker D, Ross P, Heaton N, Quaglia A. Histological heterogeneity in primary and metastatic classic combined
hepatocellular-cholangiocarcinoma: a case series. Virchows Arch 2017;471:619-29.
58. Joseph NM, Tsokos CG, Umetsu SE, Shain AH, Kelley RK, et al. Genomic profiling of combined hepatocellular-cholangiocarcinoma
reveals similar genetics to hepatocellular carcinoma. J Pathol 2019;248:164-78.
59. Bosman FT, Carneiro F, Hruban RH. WHO classification of tumours of the digestive system. Fourth edition ed. International agency
for research on cancer; 2010.
60. Moeini A, Sia D, Zhang Z, Camprecios G, Stueck A, et al. Mixed hepatocellular cholangiocarcinoma tumors: cholangiolocellular
carcinoma is a distinct molecular entity. J Hepatol 2017;66:952-61.
61. Balitzer D, Joseph NM, Ferrell L, Shafizadeh N, Jain D, et al. Immunohistochemical and molecular features of cholangiolocellular
carcinoma are similar to well-differentiated intrahepatic cholangiocarcinoma. Mod Pathol 2019;32:1486-94.
62. Audard V, Grimber G, Elie C, Radenen B, Audebourg A, et al. Cholestasis is a marker for hepatocellular carcinomas displaying beta-
catenin mutations. J Pathol 2007;212:345-52.
63. Calderaro J, Ziol M, Paradis V, Zucman-Rossi J. Molecular and histological correlations in liver cancer. J Hepatol 2019;71:616-30.
64. Kurebayashi Y, Ojima H, Tsujikawa H, Kubota N, Maehara J, et al. Landscape of immune microenvironment in hepatocellular
carcinoma and its additional impact on histological and molecular classification. Hepatology 2018;68:1025-41.